{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:10:29Z","timestamp":1768446629935,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Patients with relapsed and\/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received \u22652 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and\/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7\u20137.9), and the median number of prior treatments was 4 (interquartile range, 3\u20135). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1\u20133.8) and 7.7 months (95% CI, 5.7\u20139.7), respectively. For patients achieving \u2265PR, median PFS and OS were 10.6 months (95% CI, 8.3\u201312.9) and 16.3 months (95% CI, 13.6\u201323.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000683","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:00:09Z","timestamp":1643299209000},"page":"e683","source":"Crossref","is-referenced-by-count":4,"title":["Pomalidomide in Patients With Relapsed and\/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry"],"prefix":"10.1002","volume":"6","author":[{"given":"Ruth","family":"Wester","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands"},{"name":"Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Hematology, Amsterdam UMC, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Croockewit","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Libourel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"de Waal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Center Leeuwarden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboudumc, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"R1-20231126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"R2-20231126","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma.","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R3-20231126","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20231126","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"R5-20231126","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20231126","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"R7-20231126","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"R8-20231126","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"R9-20231126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"R10-20231126","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.","volume":"188","author":"Siegel","year":"2020","journal-title":"Br J Haematol"},{"key":"R11-20231126","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3324\/haematol.2015.137083","article-title":"Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma.","volume":"101","author":"Weisel","year":"2016","journal-title":"Haematologica"},{"key":"R12-20231126","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial.","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R13-20231126","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/bloodadvances.2019000539","article-title":"Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone.","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"key":"R14-20231126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","article-title":"The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.","volume":"39","author":"Dinmohamed","year":"2015","journal-title":"Leuk Res"},{"key":"R15-20231126","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"R16-20231126","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"R17-20231126","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase \u00bd open-label study.","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"R18-20231126","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R19-20231126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"R20-20231126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-135874","article-title":"Apollo: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM).","volume":"138","author":"Dimopoulos","year":"2020","journal-title":"Blood"},{"key":"R21-20231126","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase \u00bd study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"R22-20231126","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13063-015-0920-x","article-title":"Risk of selection bias in randomised trials.","volume":"16","author":"Kahan","year":"2015","journal-title":"Trials"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:05:14Z","timestamp":1702922714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000683","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}